Autogenous replicon particle (ARP) vaccines for porcine reproductive and respiratory syndrom virus (PRRSV)

Award Information
Agency:
Department of Agriculture
Branch
n/a
Amount:
$79,920.00
Award Year:
2007
Program:
SBIR
Phase:
Phase I
Contract:
2007-33610-18035
Award Id:
83605
Agency Tracking Number:
2009-01061
Solicitation Year:
n/a
Solicitation Topic Code:
n/a
Solicitation Number:
n/a
Small Business Information
Sirrah LLC (Currently HARRISVACCINES, INC.)
2310 150th St, Ames, IA, 50014
Hubzone Owned:
N
Minority Owned:
N
Woman Owned:
N
Duns:
n/a
Principal Investigator:
Matthew Erdman
(515) 294-7898
merdman@iastate.edu
Business Contact:
Delbert Harris
CTO
(515) 294-1664
hharris@iastate.edu
Research Institution:
n/a
Abstract
There is a clear and immediate need for improved PRRSV vaccines. PRRS is estimated to cost pork producers in the U.S. nearly $600 million annually and with a national eradication effort being proposed, the need for a second generation vaccine tool that is effective and safe is crucial. The use of a vector such as replicon particles (RP) merges subunit and modified live technologies to safely induce protective immunity by mimicking natural infection. The PD and collaborators have recently demonstrated the effectiveness of using RP vaccines in pigs and the importance of co-expressing PRRSV GP5 and M proteins in protection against PRRS. We have also described a method of producing autogenous replicon particle (ARP) vaccines using clinical samples from infected pigs. In this study, the feasibility of producing ARP vaccines in a timely matter will be studied and compared to the production time of traditional autogenous vaccines. The effectiveness and safety of the PRRSV ARP vaccine will be determined via comparison to currently available vaccines for PRRS including modified live vaccine (MLV) and traditional autogenous killed vaccine. It is anticipated that the PRRSV ARP vaccine along with the advantages of safety, specificity, and decreased production time will exhibit comparable or superior performance compared to other vaccines in a vaccination-challenge model and as measured by clinical signs, lesions, and viral load. We believe that a novel competitive PRRSV product would generate rapid market share growth due to improved production for the customer and compatibility with eradication programs.

* information listed above is at the time of submission.

Agency Micro-sites


SBA logo

Department of Agriculture logo

Department of Commerce logo

Department of Defense logo

Department of Education logo

Department of Energy logo

Department of Health and Human Services logo

Department of Homeland Security logo

Department of Transportation logo

Enviromental Protection Agency logo

National Aeronautics and Space Administration logo

National Science Foundation logo
US Flag An Official Website of the United States Government